From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules: A. Woodland, R. Grimaldi, T. Luksch, L.A.T. Cleghorn, K.K. Ojo, W.C. Van Voorhis, R. Brenk, J.A. Frearson, I.H. Gilbert and P.G. Wyatt ChemMedChem, 2013, 8(7), 1127-1137 Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors, S. Brand, L.A.T. Cleghorn, S.P. McElroy, D.A. Robinson, V.C. Smith, I. Hallyburton, J.R. Harrison, N.R. Norcross, D. Spinks, T. Bayliss, S. Norval, L. Stojanovski, L.S. Torrie, J.A. Frearson, R. Brenk, A.H. Fairlamb, M.A.J. Ferguson, K.D. Read, P.G. Wyatt and I.H. Gilbert J. Med. Chem., 2012, 55(1), 140–152 Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors, D. Spinks, L.S. Torrie, S. Thompson, J.R. Harrison, J.A. Frearson, K.D. Read, A.H. Fairlamb, P.G. Wyatt and I.H. Gilbert ChemMedChem 2011, 7(1), 95-106. Identification of Inhibitors of the Leishmania cdc2-Related Protein Kinase CRK3. L.A.T. Cleghorn, A. Woodland, I.T. Collie, L.S. Torrie, N. Norcross, T. Luksch, C. Mpamhanga, R.G. Walker, J.C. Mottram, R. Brenk, J.A. Frearson, I.H. Gilbert and P.G. Wyatt, ChemMedChem, 2011, 6(12), 2214-2224 N-myristoyltransferase inhibitors as new leads to treat sleeping sickness, J.A. Frearson, S. Brand, S.P. McElroy, L.A.T. Cleghorn, O. Smid, L. Stojanovski, H.P. Price, M.L.S. Guther, L.S. Torrie, D.A. Robinson, I. Hallyburton, C.P. Mpamhanga, J.A. Brannigan, A.J. Wilkinson, M. Hodgkinson, R. Hui, W. Qiu, O.G. Raimi, D.M.F. van Aalten, R. Brenk, I.H. Gilbert, K. D. Read, A.H. Fairlamb, M.A.J. Ferguson, D.F. Smith and P.G. Wyatt, Nature 2010, 464(7289), 728-732